Table 2. Comparison of primary and key secondary outcomes during the six-month intervention period between study groups.

Outcomes	Placebo¶	SP bimonthly¶					AS+AQ bimonthly¶				AS+AQ monthly¶
	Episodes	Rate*	Episodes	Rate*	PE (95% CI)	p-value	Episodes	Rate*	PE (95% CI)	p-value	Episodes	Rate*	PE (95% CI)	p-value
Total OPD attendance	684	1053.8	554	974.1	1.0 (−6.3 to 7.8)	0.782	556	1003.9	3.0 (−10.5 to 4.1)	0.420	497	911.8	4.9 (−2.3 to 11.6)	0.180
Malaria with any parasitaemia	183	394.4	112	267.9	24.3 (14.1 to 33.4)	<0.001	109	282.1	17.4 (6.3 to 27.2)	0.003	44	104.0	69.1 (62.9 to 74.2)	<0.001
Malaria with high density (>7000 parasites /µl)	137	297.7	80	181.6	31.0 (19.7 to 40.8)	<0.001	77	208.9	20.4 (7.8 to 31.4)	0.002	34	73.6	70.9 (64.0 to 76.5)	<0.001
Anaemia (Hb<8.0 g/dl)	64	151.2	33	82.1	30.8 (6.4 to 48.9)	0.017	42	113.7	31.7 (7.0 to49.8)	0.016	26	63.4	45.3 (24.7 to 60.3)	<0.001
Malaria anaemia	20	10.2	15	6.1	36.2 (−16.7 to 65.2)	0.145	14	7.0	26.7 (−33.0 to 59.6)	0.307	2	1.7	82.1 (53.7 to 93.1)	<0.001
All cause admissions	25	2.4	18	2.8	−16.7 (−142 to 39.9)	0.598	9	2.7	−12.5 (−194 to 66.9)	0.980	10	2.4	0.0 (−222.0 to 53.7)	0.687
Malaria admissions	19	1.9	11	1.7	7.4 (−199 to 71.4)	0.898	7	2.1	−10.5 (−815 to 55.9)	0.368	7	1.7	15.1 (−281.8 to 81.1)	0.670

^*PE: protective efficacy = (1−rate ratio)^*100; rate ratio was ^¶adjusted for age at enrolment and bednet use